Polaris’ lead candidate, ADI-PEG 20 is in late-stage trial for various cancers. Topline data from phase 2/3 trial for mesothelioma is expected this month. Polaris expects 2 new drug approvals by 2025.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.